Clinical Trial Update: Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose bortezomib for bone formation in patients with smoldering multiple myeloma; the study was terminated with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: University of Utah | Conditions: Cancer, Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2015-11-30